IT - EN
About Us

About UsHistory

Founded 90 years ago
 
1926   

Recordati is founded in Correggio - Reggio Emilia - as "Laboratorio Farmacologico Reggiano" by G. Recordati.

1953  

Recordati moves to a new facility in Milano

1961   An exclusive license agreement is signed with Syntex (now Roche) subsequently renewed until the year 2005.
     
1984   Recordati is listed on the Italian Stock Exchange
1995   Incorporation of the Spanish subsidiary, known today as Recordati Espana, in Madrid
1997   First launch Zanidip ® (lercanidipine).
1999  

Acquisition of the pharmaceutical company Doms Adrian in France to ensure a direct presence in the second European market.

2000   Acquisition of the French pharmaceutical group Bouchara
2001  

Establishment of Bouchara Recordati in France after the reorganization of the French pharmaceutical companies acquired in 1999 and 2000.
Conversion of all savings shares into ordinary shares and subsequent 2:1 stock split.

2002  

The U.K. Medicines Control Agency granted a Product License (marketing approval) for Zanidip® (lercanidipine) 20 mg tablets.

2003   The 20mg strength of lercanidipine was lauched in Germany, France and Australia
2004   The pharmaceutical pipeline is strengthened through the launch of new drugs
2005  

Acquisition of Merckle Recordati in Germany
4:1 stock split. Four new shares issued in replacement of each outstanding share.
Establishment of Recordati Pharmaceuticals in the United Kingdom.
Establishment of Recordati Hellas Pharmaceuticals S.A in Greece.
Opening of a new plant in Ireland.

2006  

Acquisition of the pharmaceutical activities of the Grupo Jaba in Portugal
BfArM (the German medicines agency) approves Zanitek®/Zanipress®, a fixed combination of lercanidipine and enalapril.

2007   First launch of Zanipress®.
Acquisition of Orphan Europe.
2008  

Acquisition of FIC and FIC Médical, a pharmaceutical services network operating in Russia and other C.I.S. countries.
Acquisition of Yeni Ilaç, a Turkish pharmaceutical company

2009   Acquisition of Herbacos-Bofarma, a pharmaceutical company present in the Czech and Slovak Republics.
European Marketing Authorization obtained for the medicinal products Urorec® and Silodyx™ 4 mg, 8 mg, hard capsules, intended for treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Carbaglu® (carglumic acid) approved by the Food and Drug Administration (FDA) in the U.S. for the treatment of NAGS deficiency.
2010  

Acquisition of ArtMed International, a company dedicated to the promotion of pharmaceutical products in Romania.
Positive outcome of the Decentralized Procedure for the approval of pitavastatin (Livazo®, Alipza® and other brands) in Europe.
Signature of a European licensing agreement with Nymox Pharmaceutical Corporation for the development and commercialization of NX-1207, Nymox’s Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

2011  

European approval to extend the use of Carbaglu® (carglumic acid) to the three main organic acidaemias.
Acquisition of the Turkish pharmaceutical company Frik Ilaç.

2012  

Acquisition of OTC products in Germany, Poland, Russia and in Italy. Acquisition of a portfolio of products for the treatment of rare diseases in the U.S.A.
Acquisition of Farma-Projekt, a polish pharmaceutical company.
European license agreement with Erytech for Graspa® (L-asparaginase encapsulated in homologous red blood cells) in development for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.

2013
 

Acquisition of 67% of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana, a suburb of Tunis. Acquisition of 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza.

2014  
License agreement with Apricus Biosciences Inc. for the marketing and sale of Vitaros® (alprostadil) for the treatment of erectile dysfunction.
Carbaglu® (carglumic acid) granted orphan drug designation in the U.S. for the treatment of organic acidemias (OAs).
License agreement with Plethora Solutions for the commercialization of Fortacin™ (lidocaine and prilocaine) for the treatment of premature ejaculation.
Acquisition of an additional 23% of the share capital of Opalia Pharma S.A.
 
2015  
Subsidiaries of the business dedicated to treatments for rare diseases were established in Brazil, Mexico and Colombia. 
Carbaglu® (carglumic acid) was authorized for sale by Health Canada for the treatment of hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).
 
2016   Acquisition of the Italian pharmaceutical company Italchimici S.p.A..
Acquisition of the Swiss pharmaceutical company Pro Farma AG.
License agreement with AP-HP (Assistance Publique – Hopitaux de Paris) for the development and commercialization of a treatment for patients affected by Maple Syrup Urine Disease (MSUD).
License agreement with Gedeon Richter to commercialize cariprazine, a novel atypical antipsychotic.
 
2017  
Cystadrops® approved in Europe.
Agreement with the Meyer Hospital in Florence (Italy) for the development of a treatment for pre-term babies affected by retinopathy of prematurity.
Acquisition from AstraZeneca of the European rights to Seloken®/Seloken® ZOK (metoprolol succinate) and Logimax® (metoprolol succinate and felodipine).
Agreement with MimeTech for the development and commercialization of a peptidomimetic of human nerve growth factor for the treatment of neurotrophic keratitis.
Acquisition of three Bayer Consumer Health brands in France, Transipeg®, TransipegLib® and Colopeg®.
 

Cover of 'Da Speziali a Imprenditori. Storia dei Recordati' (From apothecaries to Entrepreneurs. The History of the Recordati Family), by Vittorio SironiIn 1995, Editori Laterza published a collection of books on the subjects of health and health care, including a volume entitled "Da Speziali a Imprenditori. Storia dei Recordati" (From apothecaries to Entrepreneurs. The History of the Recordati Family), by Vittorio Sironi, an account of the lives of these pharmacists-turned-entrepreneurs; a dynasty that witnessed first hand a period of dramatic change in the history of health care - the birth of the pharmaceuticals industry as we know it today. (Photo of cover)

1926 - 1950
 
Giovanni Recordati founds the Recordati company in Correggio Emilia in 1926. The company emerges from a small family apothecary dating back to the start of the 19th Century. Giovanni Recordati oversees its transformation from a herbalist to a modern drug-based scientific undertaking: the "Laboratorio Farmacologico Reggiano". Recordati enjoys a period of exciting growth and development, as the country emerges-economically and morally- from the hardship of the war. In the post-war resurgence of the Italian pharmaceutical industry, the horizons for the Recordati company appear limitless.
 
From the early portfolio of products from the Laboratorio Farmacologico Reggiano, three are still on sale in Italy: Antispasmina Colica® (1927, anti-convulsive); Solvobil® (1930, laxative and colagenic), Tefamin® (1935, heart tonic, diuretic and blood pressure reducing agent). Other products emerging from this era include (to name but some) Dintoina®, Sindrenina®, Simpamina®, Insulina Recordati®. At the same time the Laboratorio commences manufacturing of the active ingredients contained in its specialities, in order to safeguard purity.
 
From the Thirties onwards, the company extends professional and academic dialogue with the medical profession beyond the limits of its own product range to a more general academic discussion of leading-edge medical issues. In this context, in 1933 the publication "Issues in Pharmacotherapy" goes into print, containing highly practical and informative features on clinical studies. This journal is followed, at the end of the Thirties by the "Folia Cardiologica", later to become, for many years, the reference publication of the Italian Society of Cardiology.
 
1951 - 1980
 
Immediately after completing his degree, and aged just 23, Arrigo Recordati (1927-1999) takes on the management of the company, following the serious illness and subsequent death, in 1952, of his father, Giovanni. In 1953, under Arrigo Recordati’s management, the corporate headquarters and pharmaceutical plant are transferred to Milan. During this same period the company’s research operations are restructured and strengthened with the creation of a new bio-pharmaceutical research laboratory.
 
The first Recordati proprietary research originated drug is Recordil® (1959, efloxate, coronary vasodilator), followed by Remeflin® (1962, dimefline, respiratory analeptic), then Genurin®/Urispas® (1973, flavoxate, a urinary anti-spasmodic and the first drug synthesised and developed in Italy to receive FDA approval in the USA, where it is still on sale, as it is in more than 60 other countries). Next comes Antoral® (1977, tibezonium iodide, an oral antiseptic).
 
In the Fifties, the company establishes its first overseas affiliates, in Latin America; these are later sold on to other family members.
 
In the Sixties the company develops the pharmaceutical chemicals business setting up the plant at Campoverde di Aprilia (Latina) and adopting the current name "Recordati Industria Chimica e Farmaceutica".
 
In 1961, an exclusive licence agreement is signed with Syntex Corporation (now part of Roche), at that time at the leading edge of research into the study and synthesis of steroidal hormones.
 
1981 - 1984
 
Arrigo Recordati’s belief that complete transparency and professionalism in financial reporting should be a requirement even of medium-sized family owned companies, is borne out by his insistence that, in 1981, Recordati voluntarily becomes one of the first medium-sized Italian companies to submit its annual report to independent audit – already widely practised abroad but at that time rare in Italy.
 
A further belief is that small companies - provided they are managed with vigour, determination, imagination and speed - are well equipped to take on the big groups which, despite their economic strength, can also be (especially if State owned) overly bureaucratic, risk averse, slow in reaching decisions, of indeterminate strategy and with a high turnover of senior management.
 
In 1984 – a key moment in Recordati’s history - the company obtains a listing on the Milan Stock Exchange. Whilst still controlled by the Recordati family, the company thereby completes its transformation from a typical, small, family operation to a modern, professional, publicly quoted company.
 
1985 - 1995
 
The development of the pharmaceutical business continues thanks to the launch of another product originated from Recordati’s research. "Lomexin®" (1986, fenticonazole), a dermatological anti-mycotic, is the first Italian drug to pass through all registration stages of the European Union’s Committee for Proprietary Medicinal Products (CPMP). In 1995, the subsidiary known today as Recordati España (Madrid) is incorporated for the marketing of both Recordati’s proprietary pharmaceutical products and of products under licence.
 
Alongside the pharmaceutical business, the group’s pharmaceutical chemicals operations steadily assume a more significant role. By the mid-Eighties, the plant at Campoverde di Aprilia is already a well-established industrial operation, whose productivity shows consistent year-on-year growth. As the quantities of product destined for the international market continue to increase, the relative importance of Recordati’s own fine chemical requirement declines. In 1987, Recordati Corporation is incorporated (Cranford, New Jersey, USA), for the marketing of fine chemicals in North America.
 
1996 - 1999
 
Arrigo Recordati, a firm believer in Research and Development as an essential driver of the Group’s continued growth, maintains a high commitment to R&D expenditure. The most recent product originated by Recordati’s Research is Zanidip® (lercanidipine, Zanedip® in Italy) a calcium channel blocker for hypertension, fully discovered and developed by Recordati.
 
In 1996, the Medicines Control Agency (MCA) grants marketing authorisation for Zanidip® in the UK. This is followed by the granting of marketing approvals in a number of EU countries, through the Mutual Recognition Procedure (Zanidip® being the first Italian pharmaceutical product to obtain mutual recognition approval) - and in non European countries. Zanidip® represents an outstanding growth opportunity for Recordati. Its Regulatory activities continue, aimed at obtaining registration in new countries, including the USA, Canada and Japan.
 
Recordati's research and development activities in the urological field progressed, with particular attention to the area of urinary incontinence.
 
In the pharmaceutical chemicals sector, in 1998 the acquisition of a plant for the production of active ingredients and intermediates for the pharmaceutical industry is finalized in Spain. This plant was subsequently sold in 2006.
 
At the beginning of 1999 Doctor Arrigo Recordati, Chairman of the Group since 1951, passed away after a short illness. His sudden death was a great loss for Recordati but did not change the company's commitment to proceed along the path of growth and development clearly defined by him.
 
In February 1999, the Recordati Board of Directors nominated Giovanni Recordati as Chairman and CEO.
 
2000 - 2004
 
Under Giovanni Recordati's management, an expansion policy based on research and internationalisation is pursued with determination.
 
A major step on this path is achieved through the establishment of Bouchara Recordati in France, the fourth largest pharmaceutical world market, after the acquisition of the French pharmaceutical company Doms Adrian (1999) and of the pharmaceutical group Bouchara (2000).
 
Activities in support of the worldwide development of Zanidip® are successful. As of the end of 2004 lercanidipine was marketed in 69 countries (today 90 countries). License agreements in place, cover over 100 countries worldwide.
 
The 20mg strength of lercanidipine was approved in Europe and in other countries. This new formulation provides therapeutic convenience to those patients who require a higher daily dose.
 
Recordati research activity is involved in the clinical development of a fixed combination between lercanidipine and the ACE-inhibitor enalapril, which addresses the need to treat a major proportion of patients with more than one antihypertensive agent to achieve adequate blood pressure control.
 
The pharmaceutical pipeline is considerably strengthened through the launch of important drugs in the cardiovascular, gastroenterology, CNS, and respiratory therapeutic fields.
 
Conversion of all savings shares into ordinary shares and subsequent 2:1 stock split (2001)
 
2005
 
Acquisition of Merckle Recordati in Germany. With this acquisition Recordati gains access to the largest pharmaceutical market in Europe and the third largest worldwide.
 
Creation of Recordati Pharmaceuticals in the United Kingdom, fondamental step in Recordati's strategy to establish a direct presence in all the main European countries.
 
Establishment in Greece of Recordati Hellas Pharmaceuticals S.A, subsidiary headquartered in Athens . Our presence on Greek pharmaceutical market, will develop gradually through the marketing and sale of both Recordati's original products and those obtained under licence.
 
Recordati establishes a presence in Ireland with the opening of a new active pharmaceutical ingredients plant in Ringaskiddy, County Cork.
 
2006
 
Recordati enters the Portuguese pharmaceutical market directly through the acquisition of the Grupo Jaba companies thus increasing its coverage of the European pharmaceutical market.
 
A new original Recordati product is approved. Zanitek®/Zanipress®, a fixed combination of lercanidipine and enalapril was approved for sale by BfArM (the German medicines agency). This approval represents the beginning of the process which will result in the introduction of this new important product in all the European markets and beyond.
 
2007
 
The first launch of Zanipress®, Recordati’s new antihypertensive product which associates lercanidipine and enalapril in a fixed combination, took place in April in Germany.
 
Recordati enters the orphan drug market through the acquisition of Orphan Europe, a European pharmaceutical group based in Paris dedicated to the development, registration, marketing and distribution of unique drugs for the treatment of rare and orphan diseases.
 
2008
 
Recordati acquires the French companies FIC and FIC Médical which are dedicated to the registration and the promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries. FIC Médical’s organization will be the base upon which Recordati will develop its own presence in Russia and in the C.I.S. markets.
 
Recordati also acquired Yeni Ilaç, a Turkish pharmaceutical company with headquarters near Istanbul. Yeni Ilaç is a well known Turkish pharmaceutical company dedicated to the production, marketing and sales of both proprietary and licensed drugs. The acquisition of Yeni Ilaç allows the group to be present directly in a market with high growth rates, where, in addition, Recordati products have already been present successfully for some time.
 
2009
 
Recordati acquires Herbacos-Bofarma, a Czech pharmaceutical company with headquarters in Pardubice. Herbacos-Bofarma, is a well known pharmaceutical company operating in the Czech and Slovak markets with a significant portfolio of medicines in various therapeutic classes.
 
The economies of the Czech Republic and Slovakia are among the most dynamic in Central and Eastern Europe and the relative pharmaceutical markets are among the most evolved. Herbacos-Bofarma is well positioned to act as a platform for launching the new products in Recordati's pipeline in these markets.
 
2010
 
Recordati was granted Marketing Authorization by the European Commission for the medicinal products Urorec® and Silodyx™ 4 mg, 8 mg, hard capsules, intended for treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
 
The Food and Drug Administration (FDA) in the U.S. granted approval of the NDA submitted by Orphan Europe for the use of Carbaglu® (carglumic acid) in pediatric and adult patients for the treatment of acute hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS deficiency) and as maintenance therapy for chronic hyperammonaemia due to NAGS deficiency.
 
Acquisition of ArtMed International, a company dedicated to the promotion of pharmaceutical products in Romania with offices in Bucharest. Furthermore, the rights to the products currently being promoted by ArtMed were also acquired.
 
Positive outcome of the Decentralized Procedure for the approval of pitavastatin (Livazo®, Alipza® and other brands) in Europe following the communication from the Reference Member State (MHRA, Medicines and Healthcare products Regulatory Agency, UK) and the agreement of all the Concerned Member States which was received by Kowa. Pitavastatin, 1mg, 2mg and 4mg tablets, is indicated for the reduction of elevated total cholesterol (TC) and LDL-C, in adult patients with primary hypercholesterolaemia and combined (mixed) dyslipidaemia when response to diet and other non-pharmacological measures is inadequate.
 
Signature of a European licensing agreement with Nymox Pharmaceutical Corporation for the development and commercialization of NX-1207, Nymox’s Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH). Under the terms of the agreement, Recordati receives exclusive rights to develop and subsequently market and sell NX-1207 in Europe including Russia and the CIS, the Middle East, the Maghreb area of North Africa and South Africa (i.e. a total of 81 countries).
 
2011
 
Orphan Europe, the group’s wholly-owned subsidiary dedicated to treatments for rare diseases, received European approval to extend the use of Carbaglu® (carglumic acid) to treat hyperammonaemia due to either of the three main organic acidaemias.
 
Acquisition of Dr. F. Frik Ilaç A.S., a Turkish pharmaceutical company with headquarters in Istanbul. This is the second acquisition Recordati has made in Turkey. The company has a core portfolio of original prescription products both in primary care and specialist areas.
 
2012
 
Acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH & Co. oHG.
 
Acquisition of 100% of the share capital of Farma-Projekt Sp. z o.o., a Polish pharmaceutical company with headquarters in Krakow. Farma-Projekt markets drugs belonging to a variety of therapeutic areas, mainly cardiovascular and urological treatments as well as dietary supplements.
 
Acquisition of all rights to five product lines on the Russian and CIS market: Alfavit, Qudesan, Vetoron, Focus and Carnitone. The brands of the products acquired, which are OTC pharmaceuticals and dietary supplements, are very well known in Russia. The Alfavit product line in particular comprises a wide range of formulations containing vitamins and minerals and holds a leading position on the market.
 
Acquisition in Italy of the oral care line of products bearing the Dentosan® trademark from Cilag GmbH International, part of the Johnson & Johnson Family of Consumer Companies. Dentosan® is the second leading brand in the Italian oral care market at pharmacy level.
 
Subsidiary Orphan Europe and Erytech Pharma, a French biopharmaceutical company, have entered into an agreement granting Orphan Europe the exclusive rights for the commercialization and distribution of Graspa® for the treatment of Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe. Graspa®, human erythrocytes encapsulating L-asparaginase, for the treatment of hematological malignancies, is currently in pivotal Phase II/III clinical trial for ALL and will enter a Phase IIb trial in AML in Europe.
 
Signature of an agreement for the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck LLC. The acquired portfolio will be marketed in the U.S. by Recordati Rare Diseases, a wholly-owned U.S. corporation.
 
 
2013
 
Acquisition of 90% of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana, a suburb of Tunis. Opalia Pharma ranks eighth in the Tunisian pharmaceutical market and is the third largest local pharmaceutical company. The company markets branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas. Opalia manufactures most of its products in a modern, cGMP certified production facility.
 
Acquisition of 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza. Casen Fleet primarily markets drugs in the gastroenterological therapeutic area. Approximately 55% of revenue is generated by a line of products used in the preparation for colonoscopy. The main product in this line is Citrafleet®.
 

2014
 
An exclusive license agreement was entered into with Apricus Biosciences Inc., San Diego U.S.A., for the marketing and sales of Vitaros® (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries, Russia, Ukraine and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries.
 
U.S. Food and Drug Administration (FDA) granted approval of Orphan Europe’s request for orphan drug designation for the use of Carbaglu® (carglumic acid) in the treatment of organic acidemias (OAs).
 
A license agreement with Plethora Solutions Limited and Plethora Solutions Holdings Plc, U.K., for the commercialization of PSD502™ (Fortacin™), a topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation, in Europe, Russia, Commonwealth of Independent States (C.I.S.), Turkey and certain countries in North Africa was signed.


2015

In 2015 the internationalization of our rare disease business went ahead with the establishment of subsidiaries in Latina America, and in particular in Brazil, Mexico and Colombia. Furthermore, Carbaglu® (carglumic acid) was authorized for sale by Health Canada as an adjunctive therapy for the treatment of acute hyperammonaemia or as maintenance therapy for chronic hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) in pediatric and adult patients.

2016

Acquisition of Italchimici S.p.A., an Italian pharmaceutical company with over 40 years of history. It is a consolidated firm in the Italian pharmaceutical market with well-known products. The company offers therapeutical solutions mainly in the gastroenterological and respiratory areas.
 
Acquisition of Pro Farma AG, a Swiss pharmaceutical company with headquarters in Zug. Pro Farma markets specialties in selected therapeutic areas which include both prescription and OTC drugs. The main brands are Lacdigest (tilactase), Tretinac (isotretinoin) and Urocit (potassium citrate).

Partnership finalized with AP-HP (Assistance Publique – Hopitaux de Paris) under which AP-HP will grant an exclusive world-wide license for the development and commercialization of an innovative product for the treatment of acute decompensation episodes in patients affected by Maple Syrup Urine Disease (MSUD), a severe metabolic disorder.

Signed license agreement with Gedeon Richter to commercialize cariprazine, a novel atypical antipsychotic in Western Europe and in Algeria, in Tunisia and in Turkey. Cariprazine is an orally active and potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors and partial agonist at serotonin 5-HT1A receptors for the treatment of schizophrenia.
 

2017
 
European marketing authorization granted for Cystadrops®, the first eye-drop solution containing cysteamine hydrochloride approved in the European Union for “the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis". Cystadrops® eye-drop solution was developed specifically for cystinosis patients by Orphan Europe (Recordati Group).
 
Exclusive worldwide licensing agreement covering the know-how developed by the Meyer Hospital in Florence (Italy) for the development of a treatment for pre-term babies affected by retinopathy of prematurity (ROP) was signed. ROP is a potentially blinding eye disorder that primarily affects premature infants. This disorder is a rare condition, however presenting as one of the most common causes of visual loss in childhood.
 
Agreement signed with AstraZeneca for the acquisition of the rights to Seloken®/Seloken® ZOK (metoprolol succinate) and Logimax® fixed dose combination (metoprolol succinate and felodipine) treatments in Europe. Metoprolol succinate is a beta-blocker mainly indicated for the control of a range of conditions including hypertension, angina pectoris, disturbances of cardiac rhythm, maintenance treatment after myocardial infarction, and functional heart disorders with palpitations.
 
Exclusive license agreement signed with MimeTech, an Italian development stage company founded by scientists from the University in Florence, for the development and subsequent commercialization on a global basis of a low molecular weight peptidomimetic of human nerve growth factor (NGF) for the treatment of neurotrophic keratitis, a rare degenerative corneal disease initiated by an impairment of trigeminal nerve.
 
Three Bayer Consumer Health brands for the French market, Transipeg®, TransipegLib® and Colopeg®, were acquired. Transipeg® and TransipegLib® are macrogol based laxatives for the treatment of symptomatic constipation in adults and Colopeg® is a large volume bowel cleanser indicated in preparation for endoscopic exploration.